Efficacy and safety between brachytherapy combined with external beam radiation therapy and external beam radiation therapy alone for prostate cancer:a meta-analysis
Jia Pengfei1,3, Zhou Xiaoxi1, Ji Bin1, Zhao Hui2
1Department of Radiation Oncology, Affiliated Hospital of Nantong University, Nantong 226001,China; 2Department of Interventional Radiology, Affiliated Hospital of Nantong University,Nantong 226001,China; 3Medical School of Nantong University,Nantong 226001,China
Abstract：Objective To systematically evaluate the efficacy and safety of brachytherapy (BT)combined with external beam radiation therapy (EBRT) and EBRT alone for prostate cancer. Methods Databases including PubMed, Web of Science, Cochrane Library, CNKI, WanFang Data and VIP were searched from the inception to July 2018 to collect the clinical trials which comparatively analyzed the efficacy and safety between EBRT plus BT and EBRT alone for prostate cancer. According to the inclusion and exclusion criteria, data of the included studies were extracted and the methodological quality was evaluated. Then, a meta-analysis was performed using RevMan 5.3. Results Ten studies of 23 393 patients were included, in which 6 were randomized controlled trials (RCTs) and the other 4 were non-RCTs.The 3-year biochemical progression-free survival (b-PFS)[OR=2.03(95%CI:1.11 to 3.73),P=0.02]and the 5-year b-PFS of intermediate-risk patients[OR=2.27(95%CI:1.49 to 3.45),P<0.01] in the EBRT+BT group were significantly higher compared with those in the EBRT group. The 3-and 5-year b-PFS, 5-year overall survival and 5-year metastasis-free survival did not differ between two groups. in the incidence of ≥grade 2 acute[OR=1.44(95%CI:1.11 to 1.38),P<0.01] and chronic genitourinary adverse reactions[OR=3.06(95%CI:1.37 to 6.80), P<0.01],≥grade 3 acute[OR=1.75(95%CI:1.14 to 2.69), P=0.01] and chronic genitourinary adverse reactions[OR=3.41(95%CI:2.42 to 4.82), P<0.01] in the EBRT group were significantly lower than those in the EBRT+BT group. The incidence of gastrointestinal adverse reactions did not significantly differ between two groups. Conclusion Compared with EBRT alone, EBRT combined with BT can effectively improve the 3-and 5-year b-PFS, whereas increase the incidence of genitourinary adverse reactions for patients with intermediate-risk prostate cancer.
Jia Pengfei,Zhou Xiaoxi,Ji Bin et al. Efficacy and safety between brachytherapy combined with external beam radiation therapy and external beam radiation therapy alone for prostate cancer:a meta-analysis[J]. Chinese Journal of Radiation Oncology, 2019, 28(7): 509-513.
[1]韩苏军,张思维,陈万青,等. 中国前列腺癌发病现状和流行趋势分析[J]. 临床肿瘤学杂志,2013(4):330-334. DOI:10.3969/j.issn.1009-0460.2013.04.009. Han SJ,Zhang SW,Chen WQ,et al. Analysis of the present situation and epidemic trend of prostate cancer in China[J]. J Clin Oncol,2013(4):330-334. DOI:10.3969/j.issn.1009-0460.2013.04.009. [2]Kuban DA,Tucker SL,Dong L,et al. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer[J]. Int J Radiat Oncol Biol Phys,2008,70(1):67-74. DOI:10.1016/j.ijrobp.2007.06.054. [3]Dearnaley DP,Jovic G,Syndikus I,et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer. Long-term results from the MRC RT01 randomised controlled trial[J]. Lancet Oncol,2014,15(4):464-473. DOI:10.1016/S1470-2045(14)70040-3. [4]Zietman AL,Bae K,Slater JD,et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate:long-term results from proton radiation oncology group/american college of radiology 95-09[J]. J Clin Oncol,2010,28(7):1106-1111. DOI:10.1200/JCO.2009.25.8475. [5]Hoskin PJ,Rojas AM,Bownes PJ,et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer[J]. Radiother Oncol,2012,103(2):217-222. DOI:10.1016/j.radonc.2012.01.007. [6]Jadad A R,Moore R A,Carroll D,et al. Assessing the quality of reports of randomized clinical trials:is blinding necessary?[J]. Control Clin Trials,1996,17(1):1-12. DOI:10.1016/0197-2456(95)00134-4. [7]Morris WJ,Tyldesley S,Rodda S,et al. Androgen suppression combined with elective nodal and dose escalated radiation therapy (the ASCENDE-RT Trial):an analysis of survival endpoints for a randomized trial comparing a low-dose-rate brachytherapy boost to a dose-escalated external beam boost for high-and intermediate-risk prostate cancer[J]. Int J Radiat Oncol Biol Phy,2017,98(2):275-285. DOI:10.1016/j.ijrobp.2016.11.026. [8]Rodda S,Morris W J,Hamm J,et al. ASCENDE-RT:An analysis of health-related quality of life for a randomized trial comparing low-dose-rate brachytherapy boost with dose-escalated external beam boost for high-and intermediate-risk prostate cancer[J]. Int J Radiat Oncol Biol Phys,2017,98(3):581-589. DOI:10.1016/j.ijrobp.2017.02.027. [9]Mohammed N,Kestin L,Ghilezan M,et al. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer[J]. Int J Radiat Oncol Biol Phys,2012,82(1):204-212. DOI:10.1016/j.ijrobp.2010.10.009. [10]Khor R,Duchesne G,Tai KH,et al. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs. external beam radiation therapy alone for prostate cancer[J]. Int J Radiat Oncol BiolPhys,2013,85(3):679-685. DOI:10.1016/j.ijrobp.2012.07.006. [11]Dayes IS,Parpia S,Gilbert J,et al. Long-term results of a randomized trial comparing iridium implant plus external beam radiation therapy with external beam radiation therapy alone in node-negative locally advanced cancer of the prostate[J]. Int J Radiat Oncol Biol Phys,2017,99(1):90-93. DOI:10.1016/j.ijrobp.2017.05.013. [12]Sathya J R, Davis I R, Julian J A, et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate[J]. J Clin Oncol, 2005,23(6):1192-1199. DOI:10.1200/JCO.2005.06.154. [13]Vigneault E,Morton G,Parulekar WR,et al. Randomised phase Ⅱ feasibility trial of image-guided external beam radiotherapy with or without high dose rate brachytherapy boost in men with intermediate-risk prostate cancer (CCTG PR15/ NCT01982786)[J]. Clin Oncol,2018,30(9):527-533. DOI:10.1016/j.clon.2018.05.007. [14]Wilder RB,Barme GA,Gilbert RF,et al. Preliminary results in prostate cancer patients treated with high-dose-rate brachytherapy and intensity modulated radiation therapy (IMRT) vs. IMRT alone[J]. Brachytherapy,2010,9(4):341-348. DOI:10.1016/j.brachy.2009.08.003. [15]Amini A,Jones B,Jackson MW,et al. Survival outcomes of dose-escalated external beam radiotherapy versus combined brachytherapy for intermediate and high risk prostate cancer using the national cancer data base[J]. J Urol,2016,195(5):1453-1458. DOI:10.1016/j.juro.2015.11.005. [16]Soumarova R,Homola L,Perkova H,et al. Three-dimensional conformal external beam radiotherapy versus the combination of external radiotherapy with high-dose rate brachytherapy in localized carcinoma of the prostate:comparison of acute toxicity[J]. Tumori,2007,93(1):37-44. DOI:10.1177/030089160709300108. [17]Cox JD,Stetz J,Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)[J]. Int J Radiat Oncol Biol Phys,1995,31(5):1341-1346. DOI:10.1016/0360-3016(95)00060-C. [18]Pollack A,Zagars GK,Smith LG,et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer.[J]. J Clin Oncol,2000,18(23):3904-3911. DOI:10.1200/JCO.2000.18.23.3904.
2019, Vol. 28 
